Physician profile
Rosalie Lee
NPI 1174525281
$2,996.07
in general payments reported to CMS, 2019-2025
20 companies · $879 in 2025
The $879 reported for 2025 was more than what 93% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.24 · 2022: $13.45 · 2023: $914 · 2024: $1,156 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Entertainment: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.41 |
| Entertainment | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $357.25 | 2024 | Optilight |
| Dompe US, INC. | $351.15 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $312.93 | 2023-2025 | Infuse Multifocal, Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $275.40 | 2023 | Acuvue |
| Lkc Technologies, INC. | $202.29 | 2024-2025 | |
| Alcon Vision LLC | $178.82 | 2023-2025 | Simbrinza, Rhopressa, Rocklatan |
| Biotissue Holdings INC. | $146.74 | 2025 | |
| Sun Pharmaceutical Industries INC. | $124.50 | 2024 | |
| Mallinckrodt Hospital Products INC. | $121.87 | 2023 | Acthar |
| Apellis Pharmaceuticals, INC. | $121.84 | 2024 | Syfovre |
| Horizon Therapeutics Plc | $120.00 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $119.02 | 2022-2024 | Tyrvaya |
| Amgen INC. | $118.52 | 2025 | Tepezza |
| Optos, INC. | $113.97 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $111.79 | 2025 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $100.58 | 2025 | Opd-III |
| Topcon Healthcare, INC. | $60.15 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $26.01 | 2025 | Cirrus Hd-Oct |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.